Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials

Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute... Breast Cancer Res Treat (2018) 168:35–41 https://doi.org/10.1007/s10549-017-4563-3 CLINICAL TRIAL Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials 1 1,2 3 3 Filipa Lynce  · Matthew J. Blackburn  · Ling Cai  · Heping Wang  · 4 5 6 1 Larry Rubinstein  · Pamela Harris  · Claudine Isaacs  · Paula R. Pohlmann   Received: 24 October 2017 / Accepted: 1 November 2017 / Published online: 8 November 2017 © Springer Science+Business Media, LLC 2017 Abstract CTEP-sponsored phase I clinical trial was 614 days for all Purpose Breast cancer (BC) is the most commonly diag- patients. Breast cancer patients were enrolled on average nosed cancer and the second leading cause of cancer-related 790 days after initial diagnosis, while non-BC patients had death among women. Given the availability of approved a median enrollment time of 582 days (p < 0.001). Breast therapies and abundance of phase II and III clinical trials, cancer patients had more clinical responses than non-BC historically few BC patients have been referred for consid- patients (18.3% vs. 4.3%, respectively). Along with the eration of participation on a phase I trial. We were inter- higher rate of response, BC patients remained on phase I ested in determining whether clinical benefit rates differed trials longer than http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials

Loading next page...
 
/lp/springer_journal/characteristics-and-outcomes-of-breast-cancer-patients-enrolled-in-the-HM2FdBjVLe
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4563-3
Publisher site
See Article on Publisher Site

Abstract

Breast Cancer Res Treat (2018) 168:35–41 https://doi.org/10.1007/s10549-017-4563-3 CLINICAL TRIAL Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials 1 1,2 3 3 Filipa Lynce  · Matthew J. Blackburn  · Ling Cai  · Heping Wang  · 4 5 6 1 Larry Rubinstein  · Pamela Harris  · Claudine Isaacs  · Paula R. Pohlmann   Received: 24 October 2017 / Accepted: 1 November 2017 / Published online: 8 November 2017 © Springer Science+Business Media, LLC 2017 Abstract CTEP-sponsored phase I clinical trial was 614 days for all Purpose Breast cancer (BC) is the most commonly diag- patients. Breast cancer patients were enrolled on average nosed cancer and the second leading cause of cancer-related 790 days after initial diagnosis, while non-BC patients had death among women. Given the availability of approved a median enrollment time of 582 days (p < 0.001). Breast therapies and abundance of phase II and III clinical trials, cancer patients had more clinical responses than non-BC historically few BC patients have been referred for consid- patients (18.3% vs. 4.3%, respectively). Along with the eration of participation on a phase I trial. We were inter- higher rate of response, BC patients remained on phase I ested in determining whether clinical benefit rates differed trials longer than

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Nov 8, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off